The Delhi High Court, in *Intra Cellular Therapies v. Controller of Patents*, discussed key issues in pharmaceutical patent law, particularly around Section 3(d) and the coverage disclosure distinction in genus-species claims. The court’s interpretation raises questions about novelty and inventive step.
Delhi High Court Explores Disclosure and Efficacy in Patent Law
The Delhi High Court recently deliberated on significant aspects of patent law in the case of Intra Cellular Therapies v. Controller of Patents, addressing the coverage disclosure distinction in genus-species claims and the therapeutic efficacy standard under Section 3(d) of the Patents Act.
The court's analysis affirmed certain aspects of the efficacy threshold but was criticized for its treatment of coverage as disclosure. The absence of a robust engagement with the novelty standard and the inventive step raises important questions for patent practitioners.
As the court noted, the lack of clarity in prior jurisprudence on these issues contributes to legal uncertainty. By equating coverage to disclosure excessively, the court may inadvertently stifle innovation, particularly in the pharmaceutical sector where incremental advancements are pivotal.
This ruling has significant implications for legal practitioners in pharmaceutical patent litigation as it highlights the need for more thorough documentation of both novelty and inventive steps, potentially influencing future patent applications and prosecutions.
Citations
- Intra Cellular Therapies v. Controller of Patents (2026) 1 Delhi Reporter 1
